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ABSTRACT
ObjeCtive
To provide absolute and relative risk estimates of 
neonatal abstinence syndrome (NAS) based on 
duration and timing of prescription opioid use during 
pregnancy in the presence or absence of additional 
NAS risk factors of history of opioid misuse or 
dependence, misuse of other substances, non-opioid 
psychotropic drug use, and smoking.
Design
Observational cohort study.
setting
Medicaid data from 46 US states.
PartiCiPants
Pregnant women filling at least one prescription for an 
opioid analgesic at any time during pregnancy for 
whom opioid exposure characteristics including 
duration of therapy: short term (<30 days) or long term 
(≥30 days); timing of use: early use (only in the first 
two trimesters) or late use (extending into the third 
trimester); and cumulative dose (in morphine 
equivalent milligrams) were assessed.
Main OutCOMe Measure
Diagnosis of NAS in liveborn infants.
results
1705 cases of NAS were identified among 290 605 
pregnant women filling opioid prescriptions, 
corresponding to an absolute risk of 5.9 per 1000 
deliveries (95% confidence interval 5.6 to 6.2). Long 
term opioid use during pregnancy resulted in higher 
absolute risk of NAS per 1000 deliveries in the 
presence of additional risk factors of known opioid 
misuse (220.2 (200.8 to 241.0)), alcohol or other drug 
misuse (30.8 (26.1 to 36.0)), exposure to other 
psychotropic medications (13.1 (10.6 to 16.1)), and 
smoking (6.6 (4.3 to 9.6)) than in the absence of any of 
these risk factors (4.2 (3.3 to 5.4)). The corresponding 
risk estimates for short term use were 192.0 (175.8 to 
209.3), 7.0 (6.0 to 8.2), 2.0 (1.5 to 2.6), 1.5 (1.0 to 2.0), 
and 0.7 (0.6 to 0.8) per 1000 deliveries, respectively. 
In propensity score matched analyses, long term 
prescription opioid use compared with short term use 
and late use compared with early use in pregnancy 
demonstrated greater risk of NAS (risk ratios 2.05 (95% 
confidence interval 1.81 to 2.33) and 1.24 (1.12 to 1.38), 
respectively).
COnClusiOns
Use of prescription opioids during pregnancy is 
associated with a low absolute risk of NAS in the 
absence of additional risk factors. Long term use 
compared with short term use and late use compared 
with early use of prescription opioids are associated 
with increased NAS risk independent of additional risk 
factors.
Introduction
Neonatal abstinence syndrome (NAS) is a serious medi-
cal condition experienced by the newborn after in utero 
exposure to psychotropic substances.1  The symptoms 
of neonatal abstinence syndrome can range from rela-
tively minor behavioral problems such as feeding, 
sleeping, and temperature regulation difficulties to 
major problems such as seizures, failure to thrive, and 
respiratory distress. Neonatal abstinence syndrome is 
associated with substantially increased healthcare 
expenditures and its incidence has been on the rise in 
the United States.2  In utero exposure to opioids is 
reported to account for a large proportion of cases of 
total neonatal abstinence syndrome.3
Prior studies have reported a high incidence of neo-
natal abstinence syndrome (42-58%) in infants born to 
mothers using illicit opioids4  and infants born to opioid 
dependent mothers on maintenance therapy with 
methadone or buprenorphine.5 6  However, recent stud-
ies from both Europe and the US indicate high use of 
licit prescription opioids for pain management during 
pregnancy. Data from a population based registry in 
Norway revealed that 6% of pregnant women filled at 
least one opioid prescription between 2004 and 2006.7 
In all, 14% to 22% of women are reported to have filled 
at least one prescription for an opioid analgesic during 
WhAT IS AlReAdy knoWn on ThIS TopIC
The use of prescription opioids is increasingly common for treating pain in pregnancy, 
but the risk to infants as a result of this practice remains largely unknown
Numerous case reports and one small observational cohort study suggest a 
potential risk of neonatal abstinence syndrome after in utero exposure to 
therapeutic doses of prescription opioids 
The patterns of use of prescription opioids during pregnancy, such as amount, 
duration, and timing, in elevating the risk of neonatal abstinence syndrome are 
not well characterized, particularly when additional risk factors are present
WhAT ThIS STudy AddS
This large population based cohort study indicates that the risk of neonatal 
abstinence syndrome is higher in women using long term prescription opioids in 
the presence of additional risk factors including history of opioid misuse or 
dependence, alcohol or other drug misuse, exposure to non-opioid psychotropic 
medications late in pregnancy, and smoking 
In comparison, short term use of prescription opioids for treating acute pain 
during pregnancy is associated with a lower risk of deliveries of infants with with 
neonatal abstinence syndrome in the absence of other additional risk factors
Maternal use of prescription opioids late in pregnancy (through the third 
trimester) compared to use only in the first two trimesters is associated with 
greater risk of neonatal abstinence syndrome in infants
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pregnancy in the US, with prevalence of use in some 
states as high as 41%.8  9  While data specific to prescrip-
tion opioid use among pregnant women are not avail-
able for countries other than Norway and the US, data 
from the general population suggest increasing use of 
prescription opioids in Canada,10  Germany,11  Israel,12 
and the United Kingdom.13  Despite evidence of high 
and increasing use, few studies have described esti-
mates for the risk of neonatal abstinence syndrome in 
infants after in utero exposure to prescription 
non-maintenance opioid analgesics. Existing research 
consists of numerous case reports that document neo-
natal withdrawal symptoms after exposure to therapeu-
tic doses of various prescription opioids14-17  and a small 
observational study from a single medical center that 
reports symptoms of neonatal abstinence syndrome in 
10 of the 167 (5.6%) infants exposed to in utero chronic 
(≥30 days) prescription opioids.18 No population based 
estimates are available for the risk of neonatal absti-
nence syndrome in infants born to mothers using pre-
scription opioid analgesics during pregnancy.
Moreover, several additional in utero exposures that 
may increase the likelihood or severity of neonatal 
abstinence syndrome have been identified in studies of 
pregnant women with addiction. These exposures 
include alcohol misuse or non-opioid illicit drugs of 
misuse,19 20  psychotropic prescription medications 
other than opioids, notably selective serotonin re- 
uptake inhibitors and benzodiazepines,3 21-25  and 
tobacco.26-28 The impact of these additional exposures 
on the risk of neonatal abstinence syndrome in infants 
born to pregnant women using prescription opioid 
analgesics is also not well understood.
Therefore, using a nationwide cohort of Medicaid 
enrolled pregnant women, our objective was to provide 
absolute and relative risk estimates of neonatal absti-
nence syndrome based on prescription opioid duration 
and timing of use during pregnancy in the presence or 
absence of additional risk factors for neonatal absti-
nence syndrome, including history of opioid misuse or 
dependence, misuse of other substances, non-opioid 
psychotropic drug use, and smoking.
Methods
Data source and study population
Data for this study were drawn from the Medicaid Ana-
lytical eXtract files for enrollees in 46 US states and 
Washington, DC for the period of 2000 to 2007. Data for 
Arizona, Connecticut, Michigan, and Montana were not 
used because of either data unavailability or incom-
plete data. These files contain information on demo-
graphics, diagnoses and procedures performed during 
outpatient visits or inpatient stays, and outpatient filled 
prescription drugs for Medicaid enrollees. The use of 
this de-identified database for research was approved 
by the institutional review board of Brigham and Wom-
en’s Hospital.
The study population consisted of women aged 12 to 
55 years with completed pregnancies resulting in live-
born infants. Methods used for linking mothers with 
their infants have been described in detail previously.29 
We estimated the date of last menstrual period based on 
the delivery date combined with a validated algo-
rithm.30 We required women to have continuous Medic-
aid eligibility beginning from the date of last menstrual 
period to the 30th day after delivery in order to ensure 
the completeness of their healthcare claims. For inclu-
sion in our study cohort, we further required women to 
have filled at least one outpatient prescription for an 
opioid analgesic at any time during pregnancy. The fol-
lowing prescription opioid analgesics were considered: 
codeine, dihydrocodeine, fentanyl, hydrocodone, 
hydromorphone, levorphanol, meperidine, morphine, 
oxycodone, oxymorphone, pentazocin, propoxyphene, 
tapentadol, and tramadol.
Patient involvement
Since this study was conducted using de-identified 
patient data, there was no patient involvement.
additional risk factors for neonatal abstinence 
syndrome and identification of the study groups
For all women with exposure to a prescription opioid 
analgesic, we defined the following four major addi-
tional risk factors for neonatal abstinence syndrome:
•	 Documented history of opioid misuse or dependence: 
use of illicit opioids (mainly heroin) or maintenance 
therapy prescription opioids in women who are 
dependent on opioids during pregnancy is widely 
recognized to be the most important risk factor for 
neonatal abstinence syndrome.4-6 31 Therefore, we 
identified women with ICD-9 (international classifi-
cation of diseases, 9th revision) codes specific to opi-
oid misuse and opioid dependence in either inpatient 
or outpatient maternal claims at any time during 
pregnancy (appendix 1). Further, since methadone 
and buprenorphine are indicated for use in medica-
tion assisted maintenance therapy in pregnant 
women with opioid misuse or dependence, we iden-
tified women with at least one filled prescription of 
either of these agents during pregnancy as an indica-
tor for opioid misuse or dependence.
•	 Documented history of alcohol misuse or non-opioid 
drug misuse: misuse of non-opioid drugs (for exam-
ple, cocaine) as well as alcohol has been found to 
result in worse symptoms of neonatal abstinence 
syndrome in infants born to mothers who misuse 
these substances.19  20 Therefore, we used ICD-9 codes 
for misuse or dependence on alcohol or other 
non-opioid drugs in either inpatient or outpatient 
maternal claims at any time during pregnancy to 
define history of alcohol misuse or non-opioid drug 
misuse (appendix 1).
•	 Use of prescription psychotropic medications in the 
third trimester: prior research has implicated a vari-
ety of psychotropic agents as potential risk factors for 
neonatal abstinence syndrome.3  21-25 We identified 
prescription dispensings of the following psychotro-
pic medications during the 90 days prior to delivery: 
tricyclic antidepressants, selective norepinephrine 
(noradrenaline) re-uptake inhibitors, selective 
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 serotonin reuptake inhibitors, benzodiazepines, 
non-benzodiazepine anxiolytics and hypnotics, anti-
convulsants, and antipsychotics.
•	 Tobacco use: maternal smoking has also been 
reported to be associated with a higher likelihood of 
developing neonatal abstinence syndrome.27  Smok-
ing is also known to worsen symptoms of neonatal 
abstinence syndrome in women on methadone main-
tenance therapy.26  28 Therefore, we identified history 
of maternal smoking based on the presence of ICD-9 
diagnosis codes for tobacco related conditions, or 
Current Procedure Terminology codes for smoking 
counseling in inpatient or outpatient claims (appen-
dix 1), or prescriptions of anti-smoking drugs (vareni-
cline, bupropion, nicotine) in pharmacy claims.
Based on the presence or absence of these additional 
risk factors, five mutually exclusive groups were created 
hierarchically in decreasing order of the hypothesized 
strength of association with neonatal abstinence syn-
drome. The first group included pregnant women with a 
history of opioid misuse or dependence; the second 
group included pregnant women with a history of alco-
hol or non-opioid drug misuse or dependence (but no 
history of opioid misuse or dependence); the third group 
included women who filled at least one prescription for 
a non-opioid psychotropic medication during the three 
months prior to the delivery (but no history of opioid, 
alcohol, or non-opioid drug misuse or dependence); the 
fourth group included women with a history of smoking 
(but neither a history of opioid, alcohol, or non-opioid 
drug misuse or dependence nor use of non-opioid psy-
chotropic medication three months prior to the deliv-
ery); and the fifth group included women who did not 
have any of the above discussed additional risk factors 
for neonatal abstinence syndrome.
Prescription characteristics of opioid exposure 
Exposure to prescription opioids was characterized in 
terms of duration, timing of use during pregnancy, and 
total cumulative exposure:
•	 Duration of prescription opioid use: we defined the 
duration of use of prescription opioid by accumulating 
total day supply across different prescriptions for these 
agents between the last menstrual period and the deliv-
ery date. Based on the accumulated days, we dichoto-
mized duration of use of prescription opioids into short 
term use (<30 days) and long term use (≥30 days).
•	 Timing of use of prescription opioids during preg-
nancy: some authors have suggested that exposure to 
prescription opioids late in the pregnancy may be 
associated with a higher risk of neonatal abstinence 
syndrome compared to early exposure.32  33 We there-
fore categorized opioid exposure based on the timing 
of the prescription fills during pregnancy: early expo-
sure included women who had filled prescriptions 
only in the first two trimesters but who did not have a 
newly dispensed opioid prescription in the last 90 
days before delivery; late exposure included women 
who filled at least one prescription in the last 90 days 
before delivery, irrespective of earlier use. We used 
early exposure to prescription opioids as a reference 
to quantify relative risk estimates of neonatal absti-
nence syndrome for late exposure.
•	 Total cumulative dose of prescription opioids: in 
order to quantify the risk of neonatal abstinence syn-
drome according to the total amount of opioid dis-
pensed, we estimated the cumulative dose of 
prescription opioids based on all prescriptions for 
opioid analgesics filled at any time during pregnancy. 
To facilitate interpretation, opioid dose for all indi-
vidual prescriptions was converted into oral mor-
phine equivalents34 and then accumulated across 
different prescriptions.
Outcome measurement
The outcome of interest was a diagnosis of neonatal 
abstinence syndrome recorded in maternal or infant 
claims between the delivery date and the 30th day of life 
for the infant. We used both maternal and infant codes 
because an infant’s claim may be recorded under the 
mother’s identification number for the first several 
months after birth. The diagnosis of neonatal abstinence 
syndrome was defined as an ICD-9 CM code 779.5.2
We described the frequency of following complica-
tions among cases of neonatal abstinence syndrome 
using ICD-9-CM codes: preterm delivery, feeding diffi-
culties (779.3), respiratory symptoms (769-770), and 
signs of seizures (779.0, 780.3). We reported the mean 
length of hospital stay and the frequency of infant 
admission to neonatal intensive care units among cases 
of neonatal abstinence syndrome.
statistical analysis
Maternal characteristics—including demographics, 
prevalence of potential prescription opioid indications 
(pain conditions), individual prescription opioid agents 
dispensed, and additional risk factors for neonatal 
abstinence syndrome—were summarized and described 
for each of the five study groups. The characteristics of 
prescription opioid exposure, including cumulative 
days of use and cumulative dose (in oral morphine 
equivalents), during pregnancy were reported as 
median (interquartile range). Number of cases and cor-
responding absolute risks of neonatal abstinence syn-
drome along with 95% confidence intervals were 
presented based on the duration of opioid use (short 
term and long term use) and timing (early and late use).
For the relative risk estimates, crude risk ratios and 
95% confidence intervals were computed for long term 
use compared with short term use as well as for late use 
compared with early use. For risk adjustment, propen-
sity scores were estimated for long term use and late use 
in separate logistic regression models based on vari-
ables including age, geographic region, race, diagnoses 
of pain conditions, calendar year of delivery, and addi-
tional risk factors for neonatal abstinence syndrome. 
Using a nearest neighbor approach and a caliper width 
of 0.05, 1:1 propensity score matching of long term users 
with short term users and late users with early users 
was conducted in the whole cohort as well as in each of 
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the five study groups to provide adjusted risk ratios for 
all relevant comparisons. Appendix table 1 contains the 
statistics for propensity score model fit and propensity 
score matching efficiency for all the analyses. To 
account for clustering because of inclusion of multiple 
deliveries from the same mothers in our cohort, we 
derived the adjusted risk ratios using generalized esti-
mating equations with a log link and exchangeable 
working correlation matrix. This approach has been 
shown to produce reliable estimates in the analysis of 
repeated pregnancy outcomes.35
For the dose-response analysis, logistic regression 
models were fitted in each of the study groups separately 
with neonatal abstinence syndrome as the outcome vari-
able and cumulative dose of prescription opioids as the 
predictor variable. No linearity in the association between 
cumulative dose of prescription opioids and the risk of 
neonatal abstinence syndrome was assumed. The dose 
was modeled as restricted cubic splines with four knots in 
order to accommodate non-linear relations in the model.36 
Since short term users of opioids demonstrated very low 
cumulative use of opioids (the median total cumulative 
dose for short term users in the entire cohort was equal to 
135 mg oral morphine equivalents), we restricted the 
dose-response analysis to long term users only. Also, 
owing to the frequent use of illicit opioids among preg-
nant women with documented history of opioid misuse or 
dependence, it was not possible to derive accurate cumu-
lative information on opioid exposure in this group. 
Therefore, we restricted the dose-response analyses to 
long term users in the other four groups.
Finally, we conducted an additional dose-response 
analysis using similar methodology for duration of use 
in which total days of use of prescription opioids during 
pregnancy was considered as a predictor variable and 
neonatal abstinence syndrome as the outcome variable. 
This analysis, defining duration of use as a continuous 
variable, was designed to evaluate trends in the relation 
between neonatal abstinence syndrome and duration 
of opioid use as a supplemental analysis to our main 
analysis which dichotomized the duration of use into 
short term (<30 days) and long term (≥30 days). All the 
analyses were conducted using SAS 9.3 (SAS Institute).
Results
Of 1 379 450 pregnant women who met the insurance 
eligibility criteria between 2000 and 2007, we included 
290 605 (21.1%) women who filled at least one prescrip-
tion for an opioid analgesic during pregnancy. Among 
these, 4816 (1.7%) had a documented history of opioid 
misuse or dependence (group 1), 28 553 (9.8%) had a 
history of alcohol or non-opioid drug misuse or depen-
dence (group 2), 34 723 (11.9%) had at least one pre-
scription for a non-opioid psychotropic medication 
during the 3 months prior to the delivery (group 3), 
28 512 (9.8%) had a history of smoking (group 4), and 
194 001 (66.5%) had none of the four hypothesized risk 
factors for neonatal abstinence syndrome (group 5). 
The majority of women (256 494 or 88.3% of all users of 
prescription opioids) used prescription opioids for a 
short term. Codeine, oxycodone, hydrocodone, and 
propoxyphene accounted for a majority of the prescrip-
tion opioid use in each of the five groups (appendix 
table 2). Table 1  shows the utilization characteristics of 
use of prescription opioids during pregnancy in our 
cohort. The median duration of use among short term 
users ranged from four to six days and the median 
cumulative dose ranged from 126 mg to 187 mg of oral 
morphine equivalents across the five study groups. 
Among long term users, both the median duration of 
use and cumulative dose within the pregnancy were 
substantially higher in group 1 (109 days and 4017 mg, 
respectively) than in the other four groups (46 to 64 
days and 832 to 1693 mg, respectively). Tables 2  and 3 
table 1 | utilization characteristics of prescription opioids during pregnancy, Medicaid data 2000-07
Population
Prescription 
opioid use 
duration*
total number 
(% of 
population)
Cumulative days of 
prescription opioid 
use during pregnancy 
(median (iQr))
Cumulative dose (in morphine 
equivalent mg) of prescription 
opioid use during pregnancy 
(median (iQr))
Whole cohort Long term use 34 111 (11.7) 55 (35-103) 1180 (440-2775)
Short term use 256 494 (88.3) 5 (3-8) 135 (75-270)
Study groups based on hierarchical NAS risk factors†
 Group 1: Documented history of opioid drug misuse/dependence Long term use 2139 (44.4) 109 (56-196) 4017 (1579-11 388)
Short term use 2677 (55.6) 6 (3-13) 187 (90-442.5)
 Group 2: Documented history of alcohol/non-opioid drug misuse Long term use 4973 (17.4) 63 (39-123) 1495 (620-3390)
Short term use 23580 (82.6) 5 (3-10) 150 (90-316)
  Group 3: Exposure to other psychotropic medications in the third 
trimester‡ 
Long term use 7027 (20.2) 64 (39-125) 1613.5 (690-3550)
Short term use 27 696 (79.8) 5 (3-11) 162 (90-384)
 Group 4: Documented smoking history Long term use 3966 (12.9) 54 (36-96) 1068 (425-2337)
Short term use 24 546 (87.1) 5 (3-10) 145 (81-300)
 Group 5: No history of above listed four risk factors Long term use 16 006 (8.2) 46 (34-80) 832 (281-1917)
Short term use 177 995 (91.8) 4 (3-8) 126 (75-240)
IQR=interquartile range, NAS=neonatal abstinence syndrome.
*At least 30 days of prescription opioids dispensed during pregnancy was defined as long term use, and <30 days as short term use.
†Five mutually exclusive groups were created hierarchically based on the presence of four risk factors. Everyone in group 1 had a history of opioid misuse/dependence; everyone in group 2 had 
a history of alcohol/non-opioid drug misuse but no opioid misuse or dependence history; everyone in group 3 had exposure to other psychotropic medications in the third trimester but no 
history of opioid misuse/dependence or alcohol/non-opioid drug misuse; everyone in group 4 had history of smoking but no history of opioid misuse/dependence or alcohol/non-opioid drug 
misuse or exposure to other psychotropic medications in the third trimester; and everyone in group 5 had none of the four identified risk factors.
‡Other psychotropic medication included were tricyclic antidepressants, selective serotonin re-uptake inhibitors, selective norepinephrine re-uptake inhibitor, benzodiazepines, antipsychotics, 
antiepileptics, and non-benzodiazepine sedative hypnotic.
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show baseline maternal characteristics by duration of 
opioid use before and after propensity score matching 
in each group, respectively.
A total of 1705 cases of neonatal abstinence syndrome 
were identified among 290 605 pregnant women filling 
opioid prescriptions, corresponding to an absolute risk of 
5.9 per 1000 deliveries (95% confidence interval 5.6 to 
6.2). Absolute risk of neonatal abstinence syndrome was 
greater among long term users of prescription opioids 
compared with short term users overall and in each of the 
five study groups. However, the risk estimates demon-
strated substantial variation across the five groups. As 
expected, risk of neonatal abstinence syndrome was low-
est in the group of women with no risk factors (4 cases 
and <1 case per 1000 deliveries for long and short term 
users, respectively) and highest in the group containing 
women with a documented history of opioid misuse or 
dependence (220 and 192 cases per 1000 deliveries for 
long and short term users, respectively) (table 4). The pro-
pensity score adjusted risk ratios demonstrated a signifi-
cant increase in the risk of neonatal abstinence syndrome 
after long term exposure compared with short term expo-
sure in the whole cohort (risk ratio 2.05, 95% confidence 
interval 1.81 to 2.33), as well as in each of the five study 
groups (risk ratios ranging from 1.26 to 5.67).
Appendix tables 3 and 4 show maternal characteris-
tics by timing of opioid use during pregnancy before and 
after propensity score matching in each group, respec-
tively. In this comparison between women using opioids 
through the third trimester (late use) and women who 
only used opioids in the first two trimesters (early use), 
a significantly higher risk of neonatal abstinence syn-
drome was observed among late users (propensity score 
adjusted risk ratio 1.24, 95% confidence interval 1.12 to 
1.38, table 5). This trend was also observed in all study 
groups (propensity score adjusted risk ratios ranging 
from 1.48 to 2.50), except for the group with a history of 
opioid misuse or dependence (propensity score adjusted 
risk ratio 1.01, 95% confidence interval 0.89 to 1.15).
The risk of neonatal abstinence syndrome increased 
with cumulative dose of opioids during pregnancy for 
long term users in all the study groups considered for 
this analysis, reaching a plateau at higher cumulative 
doses (fig 1 ). Consistent with observations in tables 3 
and 44, higher predicted risk of neonatal abstinence 
syndrome was observed with presence of the additional 
risk factors of smoking, other psychotropic medica-
tions, and alcohol or other drug misuse at similar levels 
of doses of prescription opioids. Appendix table 5 
shows risk estimates for neonatal abstinence syndrome 
at various levels of cumulative opioid doses in each 
of  these groups. Similarly, the supplemental dose- 
response analysis, which defined duration of use as a 
continuous variable, indicated increased risk of neona-
tal abstinence syndrome with an increase in the num-
ber of days of exposure to prescription opioids during 
pregnancy (appendix fig 1).
Respiratory symptoms and feeding difficulties were 
frequently observed (30.1% and 17.1%, respectively), 
while incidence of seizures was rare (2.7%) among the 
1705 observed cases of neonatal abstinence syndrome. 
The mean (standard deviation) length of hospitalization 
for these cases was five (7) days, while for non-cases it 
was three (3) days. Preterm delivery occurred in 734 
(37.2%) of infants affected by neonatal abstinence syn-
drome and 37 347 (12.9%) of non-affected infants in our 
cohort. Additional descriptive characteristics of cases of 
neonatal abstinence syndrome are summarized in 
appendix table 6 stratified by the duration of opioid use.
discussion
Principal findings
In this large population based cohort study, we 
observed a low absolute risk of neonatal abstinence 
table 4 | estimates for the risk of neonatal abstinence syndrome (nas) based on the duration of prescription opioid use during pregnancy, Medicaid 
data 2000-07
Population
total nas cases/sample 
size
absolute nas risks per 1000 deliveries 
(95% Ci) based on duration of prescription 
opioid use
relative risks (95% Ci) for long term v 
short term prescription opioid use
long term* short term* long term short term unadjusted adjusted†
Whole cohort 810/34 111 895/256 494 23.7 (22.1 to 25.4) 3.5 (3.3 to 3.7) 6.81 (6.19 to 7.48) 2.05 (1.81 to 2.33)
Study groups based on hierarchical NAS risk factors‡
  Group 1: Documented history of opioid drug 
misuse/dependence
471/2139 514/2677 220.2 (200.8 to 241) 192.0 (175.8 to 209.3) 1.15 (1.03 to 1.28) 1.26 (1.09 to 1.45)
  Group 2: Documented history of alcohol/
non-opioid drug misuse
153/4973 166/23 580 30.8 (26.1 to 36) 7.0 (6.0 to 8.2) 4.37 (3.52 to 5.43) 4.90 (3.34 to 7.2)
  Group 3: Exposure to other psychotropic 
medications§ in the third trimester
92/7027 56/27 696 13.1 (10.6 to 16.1) 2.0 (1.5 to 2.6) 6.48 (4.65 to 9.02) 3.81 (2.44 to 5.95)
 Group 4: Documented smoking history 26/3966 36/24 546 6.6 (4.3 to 9.6) 1.5 (1 to 2) 4.47 (2.7 to 7.39) 3.71 (1.61 to 8.55)
 Group 5: No history ofour above listed f risk factors 68/16 006 123/177 995 4.2 (3.3 to 5.4) 0.7 (0.6 to 0.8) 6.15 (4.57 to 8.26) 5.67 (3.07 to 10.47)
NAS=neonatal abstinence syndrome, CI=confidence interval.
*At least 30 days of prescription opioids dispensed during pregnancy was defined as long term use and <30 days as short term use.
†Propensity score (PS) matching of long term users with short term users was used to adjust for confounding factors including age, geographic region, race, pain condition diagnoses, calendar 
year of delivery, and other NAS risk factors. Risk ratios derived using generalized estimating equations with log link and exchangeable working correlation matrix to account for clustering owing 
to inclusion of mothers with multiple deliveries in the cohort.
‡Five mutually exclusive groups were created hierarchically based on the presence of four risk factors. Everyone in group 1 had a history of opioid misuse/dependence; everyone in group 2 had 
a history of alcohol/non-opioid drug misuse but no opioid misuse or dependence history; everyone in group 3 had exposure to other psychotropic medications in the third trimester but no 
history of opioid misuse/dependence or alcohol/non-opioid drug misuse; everyone in group 4 had history of smoking but no history of opioid misuse/dependence or alcohol/non-opioid drug 
misuse or exposure to other psychotropic medications in the third trimester; and everyone in group 5 had none of the four identified risk factors.
§Other psychotropic medication included were tricyclic antidepressants, selective serotonin re-uptake inhibitors, selective nor epinephrine re-uptake inhibitor, benzodiazepines, 
antipsychotics, antiepileptics, and non-benzodiazepine sedative hypnotic.
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syndrome after in utero exposure to prescription opi-
oids in the absence of additional risk factors. The abso-
lute risk of neonatal abstinence syndrome after in utero 
exposure to prescription opioids was highest in the 
presence of history of opioid misuse or dependence, fol-
lowed by alcohol or other drug misuse, exposure to 
non-opioid psychotropic medications, and smoking. 
Long term use of prescription opioids during pregnancy 
compared with short term use and use in late preg-
nancy compared with early pregnancy increased risk of 
neonatal abstinence syndrome independent of addi-
tional risk factors.
table 5 | estimates for the risk of neonatal abstinence syndrome (nas) based on the timing of prescription opioid use during pregnancy, Medicaid data 
2000-07
Population
total nas cases/sample size
absolute nas risks per 1000 deliveries (95% Ci) 
based on timing of prescription opioid use
relative risks (95% Ci) for late v early 
prescription opioid use
late use* early use* late use early use unadjusted adjusted†
Whole cohort 1042/134 361 663/156 244 7.8 (7.3 to 8.2) 4.2 (3.9 to 4.6) 1.83 (1.66 to 2.01) 1.24 (1.12 to 1.38)
Study groups based on hierarchical NAS risk factors‡
  Group 1: Documented history of opioid 
drug abuse/dependence
571/2836 414/1980 201.3 (185.2 to 218.6) 209.1 (189.4 to 230.2) 0.96 (0.86 to 1.08) 1.01 (0.89 to 1.15)
  Group 2: Documented history of alcohol/
non-opioid drug abuse
211/14 144 108/14 409 14.9 (13 to 17.1) 7.5 (6.1 to 9.0) 1.99 (1.58 to 2.51) 1.74 (1.35 to 2.25)
  Group 3: Exposure to other psychotropic 
medications§ in the third trimester
120/20 775 28/13 948 5.8 (4.8 to 6.9) 2.0 (1.3 to 2.9) 2.88 (1.91 to 4.34) 2.50 (1.61 to 3.87)
 Group 4: Documented smoking history 38/13 366 24/15 146 2.8 (2 to 3.9) 1.6 (1.0 to 2.4) 1.79 (1.08 to 2.99) 1.85 (1.07 to 3.19)
  Group 5: No history of above listed four 
risk factors
102/83 240 89/110 761 1.2 (1 to 1.5) 0.8 (0.6 to 1.0) 1.53 (1.15 to 2.03) 1.48 (1.09 to 2.01)
NAS=neonatal abstinence syndrome, CI=confidence interval.
*Early use included filled prescriptions only in the first two trimesters but no newly dispensed opioid prescription in the last 90 days before delivery; late use included at least one filled 
prescription in the last 90 days before delivery, irrespective of earlier use.
†Propensity score (PS) matching of late users with early users was used to adjust for confounding factors including age, geographic region, race, pain condition diagnoses, calendar year of 
delivery, and other NAS risk factors. Risk ratios derived using generalized estimating equations with log link and exchangeable working correlation matrix to account for clustering due to 
inclusion of mothers with multiple deliveries in the cohort.
‡Five mutually exclusive groups were created hierarchically based on the presence of four risk factors. Everyone in group 1 had a history of opioid abuse/dependence; everyone in group 2 had a 
history of alcohol/non-opioid drug abuse but no opioid abuse or dependence history; everyone in group 3 had exposure to other psychotropic medications in the third trimester but no history 
of opioid abuse/dependence or alcohol/non-opioid drug abuse; everyone in group 4 had history of smoking but no history of opioid abuse/dependence or alcohol/non-opioid drug abuse or 
exposure to other psychotropic medications in the third trimester; and everyone in group 5 had none of the four identified risk factors.
§Other psychotropic medication included were tricyclic antidepressants, selective serotonin re-uptake inhibitors, selective nor epinephrine re-uptake inhibitor, benzodiazepines, 
antipsychotics, antiepileptics, and non-benzodiazepine sedative hypnotic.
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Comparison with other studies
The current study expands upon our limited under-
standing of the risk of neonatal abstinence syndrome 
in infants after use of prescription opioids by mothers 
during pregnancy. To date, this outcome has been 
evaluated only in one cohort study of 167 pregnant 
women with long term use of prescription opioids 
(defined as use for at least 30 days) and that study 
noted incidence of neonatal abstinence syndrome in 
5.6% of the delivered infants.18 The corresponding 
number in our study is 2.4% (810 cases/34 111 long 
term users combined across the five groups). This dif-
ference in magnitude may be because of dissimilar 
prevalence of other risk factors for neonatal absti-
nence syndrome between the two studies. Addition-
ally, in the previous study, ascertainment of neonatal 
abstinence syndrome occurred on the basis of clinical 
parameters by neonatology staff, while in the current 
study ascertainment was based on ICD-9 codes. There-
fore, the difference may also be due to the severity of 
the cases of neonatal abstinence syndrome; we expect 
the neonatal abstinence syndrome ICD-9 code to be 
applied in circumstances in which neonatal absti-
nence syndrome affects the clinical course of the 
affected infant, whereas the earlier study may classify 
very mild cases as neonatal abstinence syndrome 
based on sensitive clinical parameters.
The risk of neonatal withdrawal symptoms in infants 
born to women dependent on opioids, either using 
illicit opioids or using medication assisted maintenance 
therapy, is reported in several prior studies with limited 
sample sizes. In a cohort of 50 women who used illicit 
heroin during pregnancy, Alroomi and colleagues4 
reported signs of drug withdrawal in 21 (42%) infants, 
nine (18%) of whom experienced symptoms that were 
severe enough to warrant treatment. In a randomized 
control trial comparing outcomes between methadone 
and buprenorphine maintenance therapy for treatment 
of opioid dependence in 131 pregnant women, 57% and 
47% of the infants were reported to have required treat-
ment for neonatal abstinence syndrome in the metha-
done and buprenorphine groups, respectively.5  In the 
current study, we observed 985 (20.4%) infants with a 
recorded diagnosis of neonatal abstinence syndrome 
among 4816 women with documented history of opioid 
dependence or misuse who used at least one prescrip-
tion opioid during pregnancy. While our findings are in 
line with the comparable findings from Alroomi and 
colleagues,4  the difference between our estimates and 
the estimates reported in the randomized trial5  may 
reflect the possibility of different patient populations 
included and differential intensities of follow-up for the 
diagnosis of neonatal abstinence syndrome in these 
two studies. Of note, in our study only 18.5% of the 4816 
women actively received prescriptions for methadone 
or buprenorphine (table 1), while in the randomized 
trial 100% of the included women were on one of these 
two treatments. The trial also had a mandatory observa-
tion period of 10 days after birth for evaluation of neo-
natal abstinence syndrome, which may not be the case 
for the infants observed in the current study and hence 
it is possible that the incidence of neonatal abstinence 
syndrome reported in the current study may underesti-
mate the actual incidence.
This study is the first one to our knowledge that 
evaluates a dose-response relation between use of 
prescription opioids and the risk of neonatal absti-
nence syndrome. We observed that the risk of neona-
tal abstinence syndrome increased with higher doses 
of opioids during pregnancy for long term users, but 
reached a plateau at higher cumulative doses. This 
observation is consistent with results from a large 
meta-analysis, which indicated that at higher doses of 
methadone maintenance therapy there was no further 
dose-dependent increase in the risk of neonatal absti-
nence syndrome.37 While we excluded women with 
known opioid misuse or dependence from this analy-
sis owing to the unavailability of reliable data from 
illicit sources on opioid exposure, our results suggest 
that prior findings of limited effectiveness of a dose 
reduction of methadone, after a certain point of 
cumulative exposure, in reducing the risk of neonatal 
abstinence syndrome may extend to prescription 
non-maintenance opioids.
Clinical implications
The current study provides some important clinical 
implications. Our observation of greater risk of neona-
tal abstinence syndrome in babies born to long term 
users of prescription opioids suggests that clinicians 
should carefully weigh benefits and risks of long term 
opioid use to the developing fetus. Since long term use 
through the third trimester appears to impart greater 
risk of neonatal abstinence syndrome, minimizing the 
use of prescription opioids towards the end of preg-
nancy, when clinically reasonable, may be a strategy 
to reduce this risk. The use of prescription opioids in 
concomitance with other risk factors such as non-opi-
oid psychotropic agents and smoking should also be 
carefully considered and balanced against the pres-
ence of clinical conditions that may necessitate opioid 
use for pain control. On the other hand, the benefits 
from the short term use of prescription opioids in 
treating acute pain in the absence of additional risk 
factors during pregnancy may outweigh the potential 
risk of neonatal abstinence syndrome, since short 
term use of prescription opioids during pregnancy 
appears to result in a relatively low risk of neonatal 
abstinence syndrome. Prior research indicates that 
untreated pain in pregnancy is common and may lead 
to limited productivity and difficulties in activities of 
daily living.38  While evaluating the risk-benefit bal-
ance of prescription opioid treatment in pregnancy, it 
should also be noted that neonatal abstinence syn-
drome is a condition that is identifiable and treatable 
with pharmacological and non-pharmacological 
approaches.1
strengths and limitations
Our study has several strengths. First, the large sample 
size enabled us to stratify and evaluate the risk of neo-
natal abstinence syndrome based on the presence of 
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additional risk factors and duration of opioid use. This 
approach allowed us to conclude that the absolute risk 
of neonatal abstinence syndrome associated with 
 opioid use depends on the patient characteristics (for 
instance, smoking and use of other psychotropics) as 
well as on the patterns of opioid use (for instance, mis-
use, duration, and proximity to delivery). Next, owing 
to the availability of prescription claims data, we were 
able to quantify the amount of total prescription opi-
oids dispensed and conduct dose-response analyses for 
risk of neonatal abstinence syndrome.
Our study also has some limitations. First and fore-
most, our data source only captures prescriptions filled 
by women in an outpatient setting. Any inpatient opi-
oid use is therefore not accounted for, which may result 
in an underestimation of real use. We also did not have 
information on the amount of illicit opioid use for 
women with a history of opioid misuse or dependence. 
Prescription opioids are likely just one component of 
the opioids these women are exposed to and the weak 
association for long term versus short term use and lack 
of association for late versus early use of prescription 
opioids in this group (tables 3  and 4) likely reflects the 
lack of measurement of use of illicit opioids for this 
group in our data. Use of pharmacy dispensing data to 
quantify the amount and timing of opioid use also has 
limitations because it requires the assumption that 
women consumed all the dispensed opioids in the 
interval for which they were filled. 
Second, we relied on ICD-9 diagnosis codes to deter-
mine the outcome of neonatal abstinence syndrome. 
While we expect that infants with severe neonatal absti-
nence syndrome which impacts their clinical course 
would be assigned the ICD-9 code for this condition, it is 
possible that infants with milder symptoms may not 
carry the code, which may result in an underestimation 
of actual risk of neonatal abstinence syndrome. Owing to 
the unavailability of more detailed measures of neonatal 
abstinence syndrome, such as the Finnegan scale, this 
study does not shed any light on the severity of neonatal 
abstinence syndrome. Further, we relied on ICD-9 codes 
and relevant pharmacy claims recorded during preg-
nancy to identify maternal risk factors for neonatal absti-
nence syndrome. This approach may result in some 
misclassification of our risk factor based grouping owing 
to underestimation of the risk factors such as smoking; 
that said, we have comprehensive capture of diagnostic 
codes from inpatient and outpatient records throughout 
pregnancy, a period during which patients are under 
close surveillance for conditions that are expected to 
impact pregnancy. It is thus likely that we identified most 
pregnancies with these risk factors accurately. 
Next, our sample consisted of Medicaid enrolled 
women, who mainly represent women of lower socio-
economic status in the US. The prevalence of certain 
risk factors for neonatal abstinence syndrome, such as 
smoking and drug misuse, as well as rates of prescrip-
tion opioid use may be different in women with higher 
socioeconomic status. Therefore, the reported absolute 
risk of neonatal abstinence syndrome in the overall 
cohort may not be generalizable to other populations. 
The analyses of the effect of dose, timing, and duration 
of use are attempting to identify a biological effect of 
opioid exposure on the risk of neonatal abstinence syn-
drome and therefore should be generalizable to other 
populations. Finally, we used prescriptions of metha-
done and buprenorphine to identify women with opioid 
dependence. Although primarily used for medication 
assisted maintenance, these agents are also sometimes 
used for pain control. Therefore, some misclassification 
of women in the groups for opioid dependence or mis-
use is possible. 
Conclusions
Findings from this study indicate that long term use of 
prescription opioids compared with short term use and 
late use compared with early use are associated with 
increased risk of neonatal abstinence syndrome inde-
pendent of additional risk factors. Additional risk fac-
tors such as history of opioid misuse or dependence, 
alcohol or other drug misuse, exposure to other psycho-
tropic medications late in pregnancy, and smoking con-
tribute to greater risk of neonatal abstinence syndrome 
among infants exposed in utero to prescription opioids. 
Clinicians should carefully consider the presence of one 
or more of these risk factors in pregnant women and try 
to minimize the long term use of prescription opioids 
when clinically viable. Short term use of prescription 
opioids during  pregnancy in the absence of additional 
risk factors is associated with a very low absolute risk of 
neonatal abstinence syndrome.
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Web appendix: Supplementary material
Web figure: Risk of neonatal abstinence syndrome 
(NAS) according to cumulative duration of exposure (in 
days) to prescription opioids during pregnancy, Medic-
aid data 2000-07. *Footnote: Blue lines denote abso-
lute risk estimates, red lines denote 95% confidence 
intervals. 
